EXPLORE!

Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in CKD patients.

  790 Views

eMediNexus    08 January 2018

A recent study published in Oncotarget evaluated the safety and efficacy of ferric citrate in phosphate reduction and iron supplementation, in chronic kidney disease stage 3-5 requiring dialysis patients. In this meta-analysis, a systematic search was conducted for randomized controlled trials on the effects of ferric citrate in chronic kidney disease stage 3-5 requiring dialysis patients, from PubMed, Medline, and Cochrane databases. The results showed that ferric citrate markedly reduced serum phosphate when compared to placebo, and had a non-inferior effect compared with active treatment. In addition, ferric citrate considerably improved hemoglobin, transferrin saturation and ferritin. Meanwhile, adverse effects of constipation did not differ significantly between ferric citrate and placebo or active treatment. The findings suggested that ferric citrate effectively ameliorates hyperphosphatemia and iron deficiency in patients with chronic kidney disease stage 3-5 requiring dialysis patients. Further studies were proposed in order to assess whether the long-term use of ferric citrate can reduce the risk of cardiovascular events and all-cause mortality.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.